[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349944-105":59,"doc-detail-349944-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","erbb2-i655v-mutation-correlates-with-efficacy-of-immunotherapy-in-gallbladder-cancer-case-report","ERBB2 I655V mutation correlates with efficacy of immunotherapy in gallbladder cancer - Case report","","Gallbladder cancer is an aggressive malignancy with poor prognosis, making effective targeted strategies essential. This case report links an ERBB2 I655V mutation to treatment efficacy of combined targeted therapy and PD-1 immunotherapy. Whole-exome sequencing identified ERBB2 I655V in a patient receiving conversion surgery after anlotinib plus camrelizumab. Functional assays and bioinformatics show the mutation drives constitutive ERBB2 signaling (PI3K-AKT and MAPK-ERK), increases PD-L1 expression, and supports an immunosuppressive tumor microenvironment, consistent with clinical response.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/erbb2-i655v-mutation-correlates-with-efficacy-of-immunotherapy-in-gallbladder-cancer-case-report/349944/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/erbb2-i655v-mutation-correlates-with-efficacy-of-immunotherapy-in-gallbladder-cancer-case-report/349944.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main clinical finding regarding ERBB2 I655V in gallbladder cancer?","Question",{"text":112,"@type":113},"The ERBB2 I655V mutation is associated with improved response to immunotherapy in gallbladder cancer in the reported case.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the ERBB2 I655V mutation identified and studied?",{"text":117,"@type":113},"Whole-exome sequencing was performed on tumor tissue. In parallel, transcriptomic profiling used cell lines expressing either wild-type ERBB2 or the I655V mutant, with protein signaling and PD-L1 assessed by western blot and supportive in vitro experiments.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanisms connect ERBB2 I655V to immunotherapy efficacy?",{"text":121,"@type":113},"The I655V substitution is proposed to promote altered transmembrane dimerization and constitutive activation of ERBB2, sustaining PI3K-AKT and MAPK-ERK pathways, which upregulates PD-L1 and contributes to an immunosuppressive tumor microenvironment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349944,1790336836,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Gao et al. World Journal of Surgical Oncology (2026) 24:110  \n[https://doi.org/10.1186/s12957-026-04227-4](https://doi.org/10.1186/s12957-026-04227-4)  \nWorld Journal of Surgical Oncology  \nCASE REPORT Open Access  \nERBB2 I655V mutation correlates with efficacy of immunotherapy in gallbladder cancer  \nQiang Gao1†, Ying-nan You2†, Shuo Lian1, Chang Pan3, Zong-li Zhang1* and Kang-shuai Li 1*  \nAbstract  \nBackground Gallbladder cancer (GBC) is a highly aggressive malignancy of the digestive system with a poor prognosis. Therefore, the development of effective targeted therapeutic strategies is critical for improving survival outcomes in patients with GBC. Erb-B2 receptor tyrosine kinase 2 (ERBB2) is a proto-oncogene whose overexpression or mutation has been closely linked to the initiation and progression of various cancers.  \nMethods Whole-exome sequencing (WES) was performed on tumor tissue from a patient with advanced GBC who underwent conversion surgery following combination therapy with the multi-targeted tyrosine kinase inhibitor anlotinib and the PD-1 immune checkpoint inhibitor camrelizumab, to identify potential genomic alterations associated with treatment response. Transcriptomic profiling was conducted in cell lines transfected with plasmids encoding either wild-type ERBB2 or the I655V mutant. Western blot analysis was used to assess activation of the downstream PI3K-AKT and MAPK-ERK signaling pathways and to measure PD-L1 expression levels. Bioinformatic analyses were employed to predict the structural and functional consequences ofthe ERBB2 I655V mutation.  \nResults WES revealed that the ERBB2 I655V mutation may be associated with therapeutic response. Mechanistically, the I655V substitution resides within the GG4-like motif ofthe ERBB2 transmembrane domain and may alter the transmembrane dimerization interface, potentially promoting heterodimer formation with other ErbB family members and leading to enhanced downstream signaling. Transcriptome sequencing and in vitro experiments demonstrated that the ERBB2 I655V mutation constitutively activates ERBB2, resulting in sustained activation of the PI3K-AKT and MAPK-ERK pathways. This subsequently upregulates PD-L1 expression and contributes to an immunosuppressive tumor microenvironment, which may underline the observed clinical response to combined targeted and immunotherapy.  \nConclusions The ERBB2 I655V mutation may be associated with improved treatment response to immunotherapy in gallbladder cancer.  \nKeywords ERBB2, Gallbladder cancer, Targeted therapy, Immunotherapy, PD-L1  \n†Qiang Gao andYing-nan You contributed equally to this work.  \n*Correspondence: Zong-li Zhang  \nzzlzzl [1900@163.com](1900@163.com)  \n[Kang-shuai Li](Kang-shuai Li)  \n[likangshuai_sdu@163.com](likangshuai_sdu@163.com)  \n1Department of General Surgery, Cheeloo College of Medicine, Qilu Hospital, Shandong University, 107 West Wenhua Road, Jinan, Shandong 250012, China  \n2Department of Pediatrics, Shandong Provincial Hospital, Shandong First Medical University, Jinan, Shandong, China  \n3Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not p","cbCaiuJ8r94NzD9l","https://ap.wps.com/l/cbCaiuJ8r94NzD9l","pdf",1921151,11,"English","# Abstract\n# Introduction\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What is the main clinical finding regarding ERBB2 I655V in gallbladder cancer?\",\"answer\":\"The ERBB2 I655V mutation is associated with improved response to immunotherapy in gallbladder cancer in the reported case.\"},{\"question\":\"How was the ERBB2 I655V mutation identified and studied?\",\"answer\":\"Whole-exome sequencing was performed on tumor tissue. In parallel, transcriptomic profiling used cell lines expressing either wild-type ERBB2 or the I655V mutant, with protein signaling and PD-L1 assessed by western blot and supportive in vitro experiments.\"},{\"question\":\"What mechanisms connect ERBB2 I655V to immunotherapy efficacy?\",\"answer\":\"The I655V substitution is proposed to promote altered transmembrane dimerization and constitutive activation of ERBB2, sustaining PI3K-AKT and MAPK-ERK pathways, which upregulates PD-L1 and contributes to an immunosuppressive tumor microenvironment.\"}]","ERBB2 I655V mutation correlates with efficacy of immunotherapy in gallbladder cancer - Case report | PDF",1790086360,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09f5f29d3583c7520376a6a4d867e74a.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42a39c4a7e4d0de4b8bd214ff647406b.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb9ec7645f4ba2caaf5500b46d9ebbeb.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35b41611a3863756b7bf190776366df9.webp",980,1306]